Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer
New England Journal of Medicine · 10.08.2023 · 389 (6) · 504-513
DOI: 10.1056/nejmoa2215530 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 10.08.2023. Verfasst von Mariano Provencio und 29 weiteren Autor:innen. Beteiligte Einrichtung: From Hospital Universitario Puerta de Hierro-Majadahonda (M.P., V.C., R.S.-B., J.M.-L., A.C.-B., A.R.), Hospital Universitario Clínico San Carlos (J.…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Nivolumab. Die Arbeit wurde bisher 491-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: European Commission, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Approximately 20% of patients with non-small-cell lung cancer (NSCLC) receive a diagnosis of stage III disease. There is no current consensus regarding the most appropriate treatment for these patients. METHODS: In this open-label, phase 2 trial, we randomly assigned patients with resectable stage IIIA or IIIB NSCLC to receive neoadjuvant nivolumab plus platinum-based chemotherapy (experimental group) or chemotherapy alone (control group), followed by surgery. Patients in the experimental group who had R0 resections received adjuvant treatment with nivolumab for 6 months. The primary end point was a pathological complete response (0% viable tumor in resected lung and lymph nodes). Secondary end points included progression-free survival and overall survival at 24 months and safety. RESULTS: A total of 86 patients underwent randomization; 57 were assigned to the experimental group and 29 were assigned to the control group. A pathological complete response occurred in 37% of the patients in the experimental group and in 7% in the control group (relative risk, 5.34; 95% confidence interval [CI], 1.34 to 21.23; P = 0.02). Surgery was performed in 93% of the patients in the experimental group and in 69% in the control group (relative risk, 1.35; 95% CI, 1.05 to 1.74). Kaplan-Meier estimates of progression-free survival at 24 months were 67.2% in the experimental group and 40.9% in the control group (hazard ratio for disease progression, disease recurrence, or death, 0.47; 95% CI, 0.25 to 0.88). Kaplan-Meier estimates of overall survival at 24 months were 85.0% in the experimental group and 63.6% in the control group (hazard ratio for death, 0.43; 95% CI, 0.19 to 0.98). Grade 3 or 4 adverse events occurred in 11 patients in the experimental group (19%; some patients had events of both grades) and 3 patients in the control group (10%). CONCLUSIONS: In patients with resectable stage IIIA or IIIB NSCLC, perioperative treatment with nivolumab plus chemotherapy resulted in a higher percentage of patients with a pathological complete response and longer survival than chemotherapy alone. (Funded by Bristol Myers Squibb and others; NADIM II ClinicalTrials.gov number, NCT03838159; EudraCT number, 2018-004515-45.).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From Hospital Universitario Puerta de Hierro-Majadahonda (M.P., V.C., R.S.-B., J.M.-L., A.C.-B., A.R.), Hospital Universitario Clínico San Carlos (J.L.G.-L., C.A.R., F.H.-T.), Hospital Universitario 12 de Octubre (S.P.)…
ORCID-Profile: Javier Martín-López, Alberto Cruz-Bermúdez
Förderung
- European Commission
- Instituto de Salud Carlos III
- Ministerio de Ciencia e Innovación
- Bristol-Myers Squibb
Zitieren
APA
Provencio, M., Nadal, E., González-Larriba, J. L., Martínez-Martí, A., Bernabé, R., Bosch-Barrera, J., Casal-Rubio, J., Calvo, V., Insa, A., Ponce, S., Reguart, N., de Castro, J., Mosquera, J., Cobo, M., Aguilar, A., López Vivanco, G., Camps, C., López-Castro, R., Morán, T., …, & Romero, A. (2023). Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer. New England Journal of Medicine, 389(6), 504-513. https://doi.org/10.1056/nejmoa2215530
Vancouver
Provencio M, Nadal E, González-Larriba JL, Martínez-Martí A, Bernabé R, Bosch-Barrera J, et al. Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2023;389(6):504-513. doi:10.1056/nejmoa2215530
BibTeX
@article{Provencio2023,
author = {Provencio, Mariano and Nadal, Ernest and González-Larriba, José L and Martínez-Martí, Alex and Bernabé, Reyes and Bosch-Barrera, Joaquim and Casal-Rubio, Joaquín and Calvo, Virginia and Insa, Amelia and Ponce, Santiago and Reguart, Noemí and de Castro, Javier and Mosquera, Joaquín and Cobo, Manuel and Aguilar, Andrés and López Vivanco, Guillermo and Camps, Carlos and López-Castro, Rafael and Morán, Teresa and Barneto, Isidoro and Rodríguez-Abreu, Delvys and Serna-Blasco, Roberto and Benítez, Raquel and Aguado de la Rosa, Carlos and Palmero, Ramón and Hernando-Trancho, Florentino and Martín-López, Javier and Cruz-Bermúdez, Alberto and Massuti, Bartomeu and Romero, Atocha},
title = {Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer},
journal = {New England Journal of Medicine},
year = {2023},
volume = {389},
number = {6},
pages = {504--513},
doi = {10.1056/nejmoa2215530}
}
EUVIMED